FDA Approves TECENTRIQ HYBREZA — Genentech, Inc.

# FDA Approves Genentech's TECENTRIQ HYBREZA, Expanding Subcutaneous Administration Options for Cancer Immunotherapy Genentech announced FDA approval of TECENTRIQ HYBREZA (atezolizumab and hyaluronidase-tqjs) on September 12, 2024, marking the first subcutaneous formulation of the PD-L1 inhibitor that could enhance patient convenience and potentially increase market penetration by reducing infusion burden. The subcutaneous route may drive competitive advantages in the immunotherapy space while strengthening